tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Keratosis, Actinic D055623 3 associated lipids
Invasive Pulmonary Aspergillosis D055744 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Netherton Syndrome D056770 1 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Central Serous Chorioretinopathy D056833 1 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Candidiasis, Invasive D058365 2 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Retrognathia D063173 1 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Scorpion Stings D065008 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Swanson C et al. FK 506-based immunosuppression in clinical pancreas transplantation. 1995 Transplant. Proc. pmid:8539827
Tesi RJ et al. Conversion of pancreas transplants to FK 506 from CsA. 1995 Transplant. Proc. pmid:8539828
Wiederrecht GJ et al. Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells. 1995 Prog Cell Cycle Res pmid:9552353
Burke GW et al. Use of FK 506 in simultaneous pancreas/kidney transplantation: lack of impairment of glycemic or lipid metabolism. 1995 Transplant. Proc. pmid:8539872
Burke GW et al. The use of FK506 in simultaneous pancreas/kidney transplantation: rescue, induction, and maintenance immunosuppression. 1995 Transplant. Proc. pmid:8539874
Wennberg L et al. Immunosuppression with leflunomide and cyclosporine prevents pig-to-rat islet xenograft rejection. 1995 Transplant. Proc. pmid:8539967
Tai J et al. In vivo function of pig islet xenografts in immunosuppressed diabetic mice. 1995 Transplant. Proc. pmid:8539968
Felldin M et al. Rescue therapy with Tacrolimus (FK506) in renal transplant recipients--a multicenter analysis. 1995 Transplant. Proc. pmid:8540032
Bersztel A et al. Deoxyspergualin is synergistic with cyclosporin A, but not with FK506 in a rat heart allograft transplantation model. 1995 Transplant. Proc. pmid:8540095
Fukuzaki T et al. A protocol with FK 506 for inducing unresponsiveness to murine islet allografts. 1995 Surgery pmid:7531371
Lemster BH et al. IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy. 1995 Clin. Exp. Immunol. pmid:7531627
Chaudhuri B et al. The interaction between the catalytic A subunit of calcineurin and its autoinhibitory domain, in the yeast two-hybrid system, is disrupted by cyclosporin A and FK506. 1995 FEBS Lett. pmid:7528690
Timerman AP et al. Characterization of an exchange reaction between soluble FKBP-12 and the FKBP.ryanodine receptor complex. Modulation by FKBP mutants deficient in peptidyl-prolyl isomerase activity. 1995 J. Biol. Chem. pmid:7531689
Sandborn WJ et al. Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue. 1995 Hepatology pmid:7528712
Richter A et al. Growth inhibitory effects of FK506 and cyclosporin A independent of inhibition of calcineurin. 1995 Biochem. Pharmacol. pmid:7531976
Coghlan VM et al. Association of protein kinase A and protein phosphatase 2B with a common anchoring protein. 1995 Science pmid:7528941
Schwartz M et al. FK 506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. The US Multicenter FK 506 Dose Optimization. 1995 Transplant. Proc. pmid:7533355
Yasuhara M et al. Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. 1995 Transplant. Proc. pmid:7533356
Platz KP et al. OKT3 vs FK 506 rescue management of acute steroid-resistant and chronic rejection. 1995 Transplant. Proc. pmid:7533357
Bierer BE Mechanisms of action of immunosuppressive agents: cyclosporin A, FK506, and rapamycin. 1995 Proc. Assoc. Am. Physicians pmid:8630742
Porayko MK et al. Comparing nephrotoxicity of FK 506 and cyclosporine regimens after liver transplantation: preliminary results from US Multicenter trial. U.S. Multicenter Liver Study Group. 1995 Transplant. Proc. pmid:7533358
Mueller AR et al. The superior immunosuppressant according to diagnosis: FK 506 or cyclosporine A. 1995 Transplant. Proc. pmid:7533359
Abouljoud MS et al. Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine A US Multicenter Trial. US Multicenter Study Group. 1995 Transplant. Proc. pmid:7533360
Bäckman L et al. Whole-blood and plasma levels of FK 506 after liver transplantation: results from the US Multicenter Trial. FK506 Multicenter Study Group. 1995 Transplant. Proc. pmid:7533361
Grobecker HF et al. Cyclosporine A-induced hypertension in SHR and WKY: role of the sympatho-adrenal system. 1995 Clin Exp Pharmacol Physiol Suppl pmid:9072458
Söderdahl G et al. FK 506 improves recovery of bile secretion following orthotopic liver transplantation in man. 1995 Transplant. Proc. pmid:7533362
Mor E et al. Weight gain and lipid profile changes in liver transplant recipients: long-term results of the American FK506 Multicenter Study. 1995 Transplant. Proc. pmid:7533363
Hemenway CS et al. vph6 mutants of Saccharomyces cerevisiae require calcineurin for growth and are defective in vacuolar H(+)-ATPase assembly. 1995 Genetics pmid:8582630
Grochowicz PM et al. Synergism of castanospermine and FK 506. 1995 Transplant. Proc. pmid:7533408
Itoh S and Navia MA Structure comparison of native and mutant human recombinant FKBP12 complexes with the immunosuppressant drug FK506 (tacrolimus). 1995 Protein Sci. pmid:8563622
Tamura K et al. Inhibition of insulin production by FK 506 is caused at the transcriptional level in pancreatic beta cell when FK BP-12 content is relatively high. 1995 Transplant. Proc. pmid:7533409
Kawano K et al. Protective effect of FK 506 on hepatic injury following cold ischemic preservation and transplantation: influence on hepatic microcirculation. 1995 Transplant. Proc. pmid:7533410
Charters AR et al. Developmental expression of FK506 binding proteins and calcineurin in rat brain. 1995 Biochem. Soc. Trans. pmid:8566310
Tanabe M et al. Therapeutic synergism between low-dose FK 506 and antimetabolites in rat allogeneic heart transplantation. 1995 Transplant. Proc. pmid:7533411
Abu-Elmagd K et al. The current status of hepatic transplantation at the University of Pittsburgh. 1995 Clin Transpl pmid:8794262
Masri MA Comparative study of toxicity and efficacy of cyclosporine, cyclosporine G (OG37), FK 506, and rapamycin in BALB/c mice with fitted skin grafts. 1995 Transplant. Proc. pmid:7533412
Shapiro R et al. The superiority of tacrolimus in renal transplant recipients -- the Pittsburgh experience. 1995 Clin Transpl pmid:8794266
Jiang H et al. Immunosuppressive effects of FK 506 on rat renal allograft survival, in comparison with cyclosporine. 1995 Transplant. Proc. pmid:7533413
Bismuth H Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group. 1995 Transplant. Proc. pmid:7533415
Ochiai T et al. Japanese multicenter studies of FK 506 in renal transplantation. Japanese FK 506 Study Group. 1995 Transplant. Proc. pmid:7533419
Komori T [The change of lymphocyte subset and effect of FK506 in experimental small bowel transplantation of rats]. 1995 Nihon Geka Gakkai Zasshi pmid:7534867
Woo J et al. Combined effects of FK506 (tacrolimus) and cyclophosphamide on atypical B220+ T cells, cytokine gene expression and disease activity in MRL/MpJ-lpr/lpr mice. 1995 Clin. Exp. Immunol. pmid:7535208
Jusko WJ et al. Pharmacokinetics of tacrolimus in liver transplant patients. 1995 Clin. Pharmacol. Ther. pmid:7535213
Hadley S et al. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. 1995 Transplantation pmid:7535482
Bakhtiar R and Stearns RA Studies on non-covalent associations of immunosuppressive drugs with serum albumin using pneumatically assisted electrospray ionization mass spectrometry. 1995 Rapid Commun. Mass Spectrom. pmid:7535601
Winkler M and Christians U A risk-benefit assessment of tacrolimus in transplantation. 1995 Drug Saf pmid:7545405
Antoni FA et al. Calcineurin feedback inhibition of agonist-evoked cAMP formation. 1995 J. Biol. Chem. pmid:7499291
Dix SP et al. Re: Severe interaction between methotrexate and a macrolide-like antibiotic. 1995 J. Natl. Cancer Inst. pmid:7563209
Arnold JC and Theilmann L [Comparison between tacrolimus (FK 506) and cyclosporin in immunosuppressive therapy after liver transplantation]. 1995 Z Gastroenterol pmid:7502559
Osman A et al. Schistosoma mansoni: characterization of p50, an immunophilin. 1995 Exp. Parasitol. pmid:7537219
Tanida I et al. Cooperation of calcineurin and vacuolar H(+)-ATPase in intracellular Ca2+ homeostasis of yeast cells. 1995 J. Biol. Chem. pmid:7537264
Kelly PA et al. Tacrolimus: a new immunosuppressive agent. 1995 Am J Health Syst Pharm pmid:7552894
Koch K et al. The C-32 triacetyl-L-rhamnose derivative of ascomycin: a potent, orally active macrolactone immunosuppressant. 1995 J. Med. Chem. pmid:7537331
MacDonald AS and Sketris IS Tacrolimus in transplantation. 1995 Am J Health Syst Pharm pmid:7552906
Kawasaki M et al. [Immunosuppression and the problems in partial liver transplantation]. 1995 Nihon Rinsho Meneki Gakkai Kaishi pmid:8963785
Torii N et al. An inhibitor for calcineurin, FK506, blocks induction of long-term depression in rat visual cortex. 1995 Neurosci. Lett. pmid:7537357
Holmes JA and Twentyman PR The activity of deoxyspergualin in multidrug-resistant cells. 1995 Cancer Chemother. Pharmacol. pmid:7554042
Teraoka S et al. [Present status and problems in clinical application of tacrolimus(FK506)]. 1995 Nihon Rinsho Meneki Gakkai Kaishi pmid:8963787
Miyazawa H et al. Hamster to rat kidney xenotransplantation. Effects of FK 506, cyclophosphamide, organ perfusion, and complement inhibition. 1995 Transplantation pmid:7537396
Elitsur Y et al. FK-506 and cyclosporine A (CsA) immunomodulation of the human gut mucosal immune system. 1995 Dig. Dis. Sci. pmid:7555446
Pockley AG et al. Effect of cyclosporin A, FK506 and rapamycin on proliferation and soluble IL-2 receptor release from mitogenically stimulated rat spleen cells. 1995 Biochem. Soc. Trans. pmid:8654800
Furlan V et al. Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients. 1995 Transplantation pmid:7537398
Kobayashi I et al. Combination therapy with tacrolimus and betamethasone for a patient with X-linked auto-immune enteropathy. 1995 Eur. J. Pediatr. pmid:7556338
Mañez R et al. Anomalous pattern of IgG antibody response to primary cytomegalovirus infection after solid organ retransplantation. 1995 Transplantation pmid:7537400
Adachi M et al. IL-2-induced gene expression of protein-tyrosine phosphatase LC-PTP requires acidic and serine-rich regions within IL-2 receptor beta chain. 1995 FEBS Lett. pmid:7556630
Van Thiel DH et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. 1995 Am. J. Gastroenterol. pmid:7537444
David M et al. [Occurrence of suspicious changes in cervix cytology in women after liver transplantation]. 1995 Geburtshilfe Frauenheilkd pmid:7557217
[Experimental and clinical studies on the effectiveness of new immunosuppressive agents used in heart transplantation and transplantation-related complications]. 1995 Nihon Kyobu Geka Gakkai Zasshi pmid:7561285
Asano K et al. Generation of effector T cells in Hymenolepis nana-infected, FK-506-treated BALB/c mice. 1995 Immunol. Lett. pmid:7590919
Hisatomi K et al. Changes in the mononuclear cell subpopulations of rat cardiac transplant recipients administered FK506 for the treatment of ongoing rejection. 1995 Surg. Today pmid:7539647
Ueda M et al. A proposal of FK506 optimal dosing in living related liver transplantations. 1995 Transplantation pmid:7544035
Tamura K et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell. 1995 Transplantation pmid:7539960
Muthukkumar S et al. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. 1995 Transplantation pmid:7544036
Fisher A et al. FK506 hepatotoxicity in liver allograft recipients. 1995 Transplantation pmid:7539961
Muraki T et al. Antithrombotic effect of FK506 versus prothrombotic effect of cyclosporine in vivo. 1995 Transplantation pmid:7544038
Nash RA et al. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. 1995 Blood pmid:7540071
Ishikawa A et al. [A case of tacrolimus-induced glucose intolerance following renal allografting]. 1995 Hinyokika Kiyo pmid:7544064
Bennett WM The nephrotoxicity of immunosuppressive drugs. 1995 Clin. Nephrol. pmid:7540121
Lochmüller H et al. Immunosuppression by FK506 markedly prolongs expression of adenovirus-delivered transgene in skeletal muscles of adult dystrophic [mdx] mice. 1995 Biochem. Biophys. Res. Commun. pmid:7544122
Moro A et al. Secretion by Trypanosoma cruzi of a peptidyl-prolyl cis-trans isomerase involved in cell infection. 1995 EMBO J. pmid:7540135
Deschler DG et al. Posttransplantation lymphoproliferative disorder in patients under primary tacrolimus (FK 506) immunosuppression. 1995 Arch. Otolaryngol. Head Neck Surg. pmid:7544136
Rouvière-Fourmy N et al. 1H and 15N assignment of NMR spectrum, secondary structure and global folding of the immunophilin-like domain of the 59-kDa FK506-binding protein. 1995 Eur. J. Biochem. pmid:7544285
Sakamoto K et al. A new assay method for immunosuppressants with a tacrolimus (FK506)-like mode of action. 1995 J. Antibiot. pmid:7544337
Jindal RM and Popescu I Renal dysfunction associated with liver transplantation. 1995 Postgrad Med J pmid:7479462
Yeh WC et al. Identification and characterization of an immunophilin expressed during the clonal expansion phase of adipocyte differentiation. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7479941
Yeh WC et al. Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7479942
Ruff VA and Leach KL Direct demonstration of NFATp dephosphorylation and nuclear localization in activated HT-2 cells using a specific NFATp polyclonal antibody. 1995 J. Biol. Chem. pmid:7545680
Shaw KT et al. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7479966
Matsuo S and Okamoto K Enhancement of FK-506 activities by ganglioside (GM3) in vivo. 1995 Life Sci. pmid:7545772
Annesley TM et al. Stability of tacrolimus (FK 506) and cyclosporin G in whole blood. 1995 Ther Drug Monit pmid:7482690
Jain AB et al. Capillary blood versus arterial or venous blood for tacrolimus monitoring in liver transplantation. 1995 Transplantation pmid:7545836
Lampen A et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. 1995 Drug Metab. Dispos. pmid:8689938
Lake JR et al. The impact of immunosuppressive regimens on the cost of liver transplantation--results from the U.S. FK506 multicenter trial. 1995 Transplantation pmid:7482713
Bolman RM Advantage--FK 506: reduced chronic rejection for lung transplant recipients. 1995 Ann. Thorac. Surg. pmid:7545888
Mathew A et al. Reversal of steroid-resistant rejection in renal allograft recipients using FK506. 1995 Transplantation pmid:7482730
Keenan RJ et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. 1995 Ann. Thorac. Surg. pmid:7545889
Okamoto M et al. In situ proliferating status of mononuclear cells in rat small bowel grafts. 1995 Int J Exp Pathol pmid:7547442
Zhu D et al. Myristoylation of calcineurin B is not required for function or interaction with immunophilin-immunosuppressant complexes in the yeast Saccharomyces cerevisiae. 1995 J. Biol. Chem. pmid:7559604
Sakane T et al. [A phase II study of FK506 (tacrolimus) on refractory uveitis associated with Behçet's disease and allied conditions]. 1995 Ryumachi pmid:8594659
Stratta RJ et al. Preliminary experience with FK 506 in pancreas transplant recipients. 1995 Transplant. Proc. pmid:8539823